title: Low-dosage mitomycin C as an adjunct to trabeculectomy. A prospective controlled study.
abstract: OBJECTIVE
  To assess the advantages and adverse effects of intraoperative low-dose Mitomycin C in filtering glaucoma surgery.
  
  
  METHODS
  Sixty eyes of 48 patients undergoing surgery for uncontrolled glaucoma were randomized to two groups: one underwent standard trabeculectomy, the other had trabeculectomy with intraoperative application of 0.1 mg/ml mitomycin C. Follow-up was at least one year.
  
  
  RESULTS
  The success rate (IOP < 18 mmHg) was 96.6% in the mitomycin C group and 73.3% in the control group. Mean IOP at one year of successful cases was 11.1 +/- 3.1 mmHg in the mitomycin C group and 16.4 +/- 6.1 mmHg in controls (p < 0.0001). Two patients in the mitomycin C group (6.6%) and six (20%) in the control group needed antiglaucomatous drugs to keep IOP below 18 mmHg.
  
  
  CONCLUSIONS
  Mitomycin C is a useful adjunct to glaucoma surgery. Adverse effects at the dosage used are mainly due to hypotony and are preventable with two-layer suture. Low-dose mitomycin C may be useful in standard primary trabeculectomy.
authors.affiliation: Department of Physiopathologic Optics, University of Bologna, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Martini
authors.forename: G L
authors.initials: GL
authors.lastname: Laffi
authors.forename: C
authors.initials: C
authors.lastname: Sprovieri
authors.forename: L
authors.initials: L
authors.lastname: Scorolli
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D006801:Humans; D007429:Intraocular Pressure; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D014130:Trabeculectomy; D016896:Treatment Outcome; D014792:Visual Acuity; D014794:Visual Fields
chemical_list: D000903:Antibiotics, Antineoplastic; D009883:Ophthalmic Solutions; D016685:Mitomycin